LifeCodexx gets go ahead for Down syndrome test in Switzerland

After much controversy, the Swiss national agency for therapeutic products (Swissmedic) has approved PrenaTest, the DNA biomarker prenatal test for Down syndrome, also known as trisomy 21. The test sequences the fetal DNA circulating in the mother's blood. In June, groups representing people with Down syndrome asked the European Court of Human Rights not to recognize individuals' rights to prenatal testing for the condition, claiming that testing leads to almost universal abortions. Article

Suggested Articles

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.